A chimeric Lym-1/interleukin 2 fusion protein for increasing tumor vascular permeability and enhancing antibody uptake

Cancer Research

Volumn 56, Issue 21, 1996, Pages 4998-5004

  Hu, Peisheng ^a   Hornick, Jason L ^a   Glasky, Michelle S ^a   Yun, Aoyun ^a   Milkie, Mary N ^a   Khawli, Leslie A ^a   Anderson, Peter M ^b   Epstein, Alan L ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTAMATE AMMONIA LIGASE; HYBRID PROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY LYM 1; RECOMBINANT INTERLEUKIN 2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; BLOOD VESSEL PERMEABILITY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; GENE AMPLIFICATION; GENETIC ENGINEERING; LYMPHOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; BASE SEQUENCE; CAPILLARY PERMEABILITY; HUMANS; IMMUNOCONJUGATES; INTERLEUKIN-2; LYMPHOMA; MICE; MOLECULAR SEQUENCE DATA; RECOMBINANT FUSION PROTEINS; TISSUE DISTRIBUTION;

EID: 0029854530     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Goldenberg, D. M. Monoclonal antibodies in cancer detection and therapy. Am. J. Med., 94: 297-312, 1993.
2. Kemshead, J. T., and Hopkins, K. Uses and limitations of monoclonal antibodies (MoAbs) in the treatment of malignant disease: a review. J. Royal Soc. Med., 86: 219-224, 1993.
3. Kosmas, C., Linardou, H., and Epenetos, A. A. Advances in monoclonal antibody tumour targeting. J. Drug Target, 1: 81-91, 1993.
4. Murray, J. L. Factors for improving monoclonal-antibody targeting Diagn. Oncol., 2: 234-241, 1992.
5. Goodwin, D. A. Pharmacokinetics and antibodies J. Nucl Med., 28: 1358-1362, 1987.
6. Goldenberg, D. M. Targeting of cancer with radiolabeled antibodies. Prospects for imaging and therapy. Arch. Pathol. Lab Med., 112: 580-587, 1988.
7. Dykes, P. W., Bradwell, A. R., Chapman, C. E., and Vaughn, A. T. M. Radioimmunotherapy of cancer: clinical studies and limiting factors. Cancer Treat. Rev., 14: 87-106, 1987.
8. 111In-labeled T101 monoclonal antibody. N. Engl. J. Med., 315: 673-680, 1986.
9. Jain, R. K. Transport of molecules across tumor vasculature Cancer Metastasis Rev., 6: 559-593, 1987.
10. Jain, R. K. Determinants of tumor blood flow: a review. Cancer Res., 48: 2641-2658, 1988.
11. Sands, H. Radioimmunoconjugates. An overview of problems and promises. Antibody Immunoconj Radiopharm., 1: 213-226, 1988.
12. Sands, H. Experimental studies of radioimmunodetection of cancer: an overview. Cancer Res., 50 (Suppl.): 809s-813s, 1990.
13. Khawli, L. A., Miller, G. K., and Epstein, A. L. Effect of seven new vasoactive immunoconjugates on the enhancement of monoclonal antibody uptake in tumors. Cancer (Phila), 73 (Suppl): 824-831, 1994.
14. LeBerthon, B., Khawli, L. A., Alauddin, M., Miller, G. K., Charak, B. S., Mazumder, A., and Epstein, A. L. Enhanced tumor uptake of macromolecules induced by a novel vasoactive interleukin 2 immunoconjugate. Cancer Res., 51: 2694-2698, 1991.
15. Morgan, D. A., Ruscetti, F. W., and Gallo, R. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science (Washington DC), 193: 1007-1008, 1976.
16. Grimm, E. A., Mazumder, A., Zhang, H. Z., and Rosenberg, S. A. The lymphokine activated killer phenomenon, lysis of NK resistant fresh solid tumor cells by IL-2 activated autologous human peripheral blood lymphocytes. J. Exp Med., 155: 1823-1841, 1982.
17. Rosenstein, M., Ettinghausen, S. E., and Rosenberg, S. A. Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin-2 Immunology, 137: 1735-1742, 1986.
18. Ohkubo, C., Bigos, D., and Jain, R. K. Interleukin 2-induced leukocyte adhesion to the normal and tumor microvasculature endothelium in vivo and its inhibition by dextran sulfate implications for vascular leak syndrome Cancer Res., 51: 1561-1563, 1991.
19. Edwards, M. J., Miller, F. N., Sims, D. E., Abney, D. L., Schuschke, D. A., and Corey, T. S. Interleukin 2 acutely induces platelet and neutrophil-endothelial adherence and macromolecular leakage Cancer Res., 52: 3425-3431, 1992.
20. Damle, N. K., and Doyle, L. V. IL-2 activated human killer lymphocytes but not their secreted products mediate increase in albumin flux across cultured endothelial monolayers. J Immunol., 142: 2660-2669, 1989.
21. Hu, P., Glasky, M. S., Yun, A., Alauddin, M. M., Hornick, J. L., Khawli, L. A., and Epstein, A. L. A human-mouse chimeric Lym-1 monoclonal antibody with specificity for human lymphomas expressed in a baculovirus system. Hum. Antib. Hybrid., 6: 57-67, 1995.
22. Epstein, A. L., Marder, R. J., Winter, J. N., Stathopoulos, E., Chen, F-M., Parker, J. W., and Taylor, C. R. Two new monoclonal antibodies, Lym-1 and Lym-2, reactive with human B-lymphocytes and derived tumors, with immunodiagnostic and immunotherapeutic potential. Cancer Res., 47: 830-840, 1987.
23. Colcher, D., Hand, P. H., Nuti, M., and Schlom, J. A spectrum of monoclonal antibodies reactive with human mammary tumor cells. Proc Natl Acad Sci. USA, 78: 3199-3203, 1981.
24. 2 fragments. J. Chromatogr., 563: 243-255, 1991.
25. Khawli, L. A., Alauddin, M. M., Miller, G. K., and Epstein, A. L. Improved immunotargeting of tumors with biotinylated monoclonal antibodies and radiolabeled streptavidin. Antibody Immunoconj. Radiopharm., 6: 13-27, 1993.
26. Laemmli, U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4 Nature (Lond), 227: 680-685, 1970.
27. Anderson, P. M., Rogosheske, J. R., Ramsay, N. K. C., and Weisdorf, D. J. Biologic activity of interleukin-2 in intravenous admixtures containing antibiotic, morphine sulfate, or total parenteral nutrient solution Am. J. Hosp Pharm., 49: 608-612, 1992.
28. Frankel, M. E., and Gerhard, W. The rapid determination of binding constants for antiviral antibodies by radioimmunoassay. An analysis of the interaction between hybridoma proteins and influenza virus Mol Immunol., 16: 101-106, 1979.
29. O'Reilly, D. R., Miller, L. K., and Luckow, V. A. Baculovirus expression vectors. A laboratory manual, pp 216-229. New York Oxford University Press, 1994.
30. Bebbingtonm C. R., Renner, G., Thomson, S., King, G., Abrams, D., and Yarranton, G. T. High-level expression of a recombinant antibody from myeloma cells using glutamine synthetase as an amplifiable selectable marker. Bio-Technology (NY), 10: 169-175, 1992.
31. Samlowski, W. E., Yim, C-Y., McGregor, J. R., Kwon, O-D., Gonzales, S., and Hibbs, J. B., Jr. Effectiveness and toxicity of protracted nitric oxide synthesis inhibition during IL-2 treatment of mice. J. Immunother., 18: 166-178, 1995.
32. G-nitro-L-arginine methyl ester, an inhibitor of nitric oxide synthesis, ameliorates interleukin-2-induced capillary leak syndrome in healthy mice. J. Immunother., 18: 210-220, 1996.
33. Marincola, F. M. Interleukin-2. Biol. Ther. Cancer Updates, 4: 1-16, 1994.
34. Richards, J. M., and Lotze, M. T. IL-2 therapy. Current status and future directions. Contemp. Oncol., 34-42, 1992.
35. Gill, I., Agah, R., Hu, E., and Mazumder, A. Synergistic antitumor effects of interleukin 2 and the monoclonal antibody Lym-1 against human Burkitt lymphoma cells in vitro and in vivo Cancer Res., 49: 5377-5379, 1989.
36. Biddle, W. C., Pancook, J., Goldrosen, M., Han, T., Foon, K. A., and Vaickus, L. Antibody-dependent, cell-mediated cytotoxicity by an anti-Class II murine monoclonal antibody, effects of recombinant interleukin 2 on human effector cell lysis of human B-cell tumors Cancer Res., 50: 2991-2996, 1990.
37. Morgan, A. C., Jr., Sullivan, W., Graves, S., and Woodhouse, C. S. Murine monoclonal IgG3 to human colorectal tumor-associated antigens: enhancement of antibody-dependent cell-mediated cytotoxicity by interleukin 2. Cancer Res., 49: 2773-2776, 1989.
38. Hank, J. A., Robinson, R. R., Surfus, J., Mueller, B. M., Reisfeld, R. A., Cheung, N-K., and Sondel, P. M. Augmentation of antibody-dependent cell-mediated cytotoxicity following in vivo therapy with recombinant interleukin 2 Cancer Res., 50: 5234-5239, 1990.
39. Vuist, W. M. J., Buitenen, M. A. d. R., Hekman, A., Rumke, P., and Melief, C. J. M. Potentiation by interleukin 2 of Burkitt's lymphoma therapy with anti-pan B (anti-CD19) monoclonal antibodies in a mouse xenotransplantation model. Cancer Res., 49: 3783-3788, 1989.
40. Tsai, S-C. J., Gansbacher, B., Tait, L., Miller, F. R., and Heppner, G. H. Induction of antitumor immunity by interleukin-2 gene-transduced mouse mammary tumor cells versus transduced mammary stromal cells. J. Natl. Cancer Inst., 85: 546-553, 1993.
41. Katsanis, E., Orchard, P. J., Bausero, M. A., Gorden, K. B., McIvor, R. S., and Blazar, B. R. Interleukin-2 gene transfer into murine neuroblastoma decreases tumorigenicity and enhances systemic immunity causing regression of preestablished retropentoneal tumors. J. Immunother., 15: 81-90, 1994.
42. Visseren, M. J. W., Koot, M., van der Voort, E. I. H., Gravestein, L. A., Shoenmakers, H. J., Kast, W. M., Zijlstra, M., and Melief, C. J. M. Production of interleukin-2 by EL-4 tumor cells induces natural killer cell- and T cell-mediated immunity. J. Immunother., 15: 119-128, 1994.
43. Ohira, T., Ohe, Y., Heike, Y., Podack, E. R., Olsen, K. J., Nishio, K., Nishio, M., Miyahara, Y., Funayama, Y., Ogasawara, H., Anoka, H., Kato, H., and Saijo, N. Gene therapy for Lewis lung carcinoma with tumor necrosis factor and interleukin 2 cDNAs co-transfected subline. Gene Ther., 1: 269-275, 1994.
44. Uchiyama, A., Hoon, D. S. B., Morisaki, T., Kaneda, Y., Yuzuki, D. H., and Morton, D. L. Transfection of interleukin 2 gene into human melanoma cells augments cellular immune response. Cancer Res., 53 949-952, 1993.
45. Cignetti, A., Guarini, A., Carbone, A., Forni, M., Cronin, K., Forni, G., Gansbacher, B., and Foa, R. Transduction of the IL2 gene into human acute leukemia cells: induction of tumor rejection without modifying cell proliferation and IL2 receptor expression J. Natl. Cancer Inst., 86: 785-791, 1994.
46. Fell, H. P., Gayle, M. A., Grosmaire, L., and Ledbetter, J. A Genetic construction and characterization of a fusion protein consisting of a chimeric F(ab′) with specificity for carcinomas and IL-2. J. Immunol., 146: 2446-2452, 1991.
47. Gillies, S. D., Reilly, E. B., Lo, K-M., and Reisfeld, R. A. Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells. Proc. Natl. Acad Sci. USA, 89: 1428-1432, 1992.
48. Gillies, S. D., Young, D., Lo, K-M., and Roberts, S. Biological activity and in vivo clearance of antitumor antibody/cytokine fusion proteins. Bioconjugate Chem., 4: 230-235, 1993.
49. Sabzevari, H., Gillies, S. D., Mueller, B. M., Pancook, J. D., and Reisfeld, R. A. A recombinant antibody-interleukin 2 fusion protein suppresses growth of hepatic human neuroblastoma metastases in severe combined immunodeficiency mice. Proc. Natl Acad. Sci. USA, 91: 9626-9630, 1994.
50. Savage, P., So, A., Spooner, R. A., and Epenetos, A. A. A recombinant single chain antibody interleukin-2 fusion protein. Br J Cancer, 67: 304-310, 1993.
51. Naramura, M., Gillies, S. D., Mendelsohn, J., Reisfeld, R. A., and Mueller, B. M. Mechanisms of cellular cytotoxicity mediated by a recombinant antibody-IL2 fusion protein against human melanoma cells Immunol. Lett., 39: 91-99, 1994.
52. Xiang, J., Liu, E. Moyana, T., and Qi, Y. Single-chain antibody variable region-targeted interleukin-2 stimulates killing of human colorectal carcinoma cells Immunol. Cell Biol., 72: 275-285, 1994.
53. Bei, R., Schlom, J., Kashmiri, S. V. S. Baculovirus expression of a functional single-chain immunoglobulin and its IL-2 fusion protein. J. Immunol Methods, 168: 245-255, 1995.